论文部分内容阅读
(2″R)-4′-O-四氢吡喃阿霉素(THP)对白血病L-1210和P 388、Lewis肺癌、B-16黑色素瘤和结肠腺癌38的疗效优于ADM。 THP治疗恶性血液病经Ⅱ期临床研究表明有相当疗效。43名患者(何杰金氏淋巴瘤、非何杰金氏淋巴瘤、急性白血病各2、20和21例),其中35例曾接受过化疗,均单一给予THP治疗。急性白血病人静注每日15～20mg/m~2,连用3～5天;恶性淋巴瘤患者则采取两个方案:每次40～50mg/m~2,每3周1次和每次15～30mg/m~2,每周1次。以上均重复3次以上。结果表明,完全缓解(CR)、部分缓解(PR)和总有效率(CR十PR):急性白血病为
(2 "R) -4’-O-tetrahydropyranopyrexidin (THP) is superior to ADM in leukemia L-1210 and P 388, Lewis lung carcinoma, B-16 melanoma and colon adenocarcinoma 38. THP Treatment of hematologic malignancies by Phase II clinical study showed considerable efficacy in 43 patients (Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, acute leukemia, 2,20 and 21 cases), of which 35 cases had received Chemotherapy, are given a single treatment of THP .Acute leukemia intravenous 15 ~ 20mg / m ~ 2, once every 3 to 5 days; patients with malignant lymphoma are two programs: each 40 ~ 50mg / m ~ 2, each 3 times a week and 15 ~ 30mg / m ~ 2 each time, once a week.The above were repeated more than 3 times.The results showed that complete remission (CR), partial remission (PR) and total effective rate : Acute leukemia is